Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This study found that combining hair transplantation with platelet-rich plasma led to significantly better outcomes, such as reduced hair loss area and increased hair regeneration, compared to hair transplantation alone in patients with androgenic alopecia.

In this randomized control trial, researchers reported that topical calcipotriol was more effective than topical tacrolimus in promoting hair growth for patients with alopecia areata over a 6-month period, with a statistically significant difference in efficacy.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.

This study found that gentamicin-loaded exosomes derived from bovine leukocyte spleen extract enhanced antimicrobial activity and promoted tissue regeneration in infected diabetic mouse wounds, suggesting a potential innovative therapeutic strategy for diabetic foot ulcers by combining infection control with pro-regenerative and immunomodulatory effects.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This review concludes that methotrexate remains an effective and safe first-line treatment for various inflammatory and immune-mediated skin conditions in children, despite the rise of biologic therapies.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.

In this study, PTH-CBD effectively prevented and partially reversed chemotherapy-induced alopecia in mice, with pretreatment offering a better cosmetic outcome compared to therapeutic administration after hair loss onset.

In this study, combining thalidomide with CHOP treatment showed a significantly higher effective rate in treating peripheral T-cell lymphoma compared to CHOP alone, while both regimens were associated with similar levels of adverse reactions.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This case report describes a 12-year-old boy who developed severe shingles with skin erosion and hair loss despite early aciclovir treatment after a stem-cell transplant for relapsed acute myeloid leukemia.

This case report describes a non-thymoma-associated exfoliative dermatitis in an 8-year-old cat, where treatment with cyclosporine A alongside prednisolone and antibiotics resolved skin lesions without relapse after an initial recurrence.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.

This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This study introduced hydrogel microneedles loaded with palladium nanoparticles, which utilize the inherent cytotoxicity of polyethyleneimine to enhance the effectiveness of doxorubicin in treating melanoma, achieving a tumor inhibition rate of up to 98% in a murine model.

In this study, researchers found that cyclophosphamide treatment unexpectedly reduced splenic melanin deposition in a murine model, whereas this effect was down-regulated more by the normal and dystrophic catagen phase of the hair cycle.

This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.